in Patients with Rheumatoid Arthritis and Osteoarthritis

Oct 9, 2016 by in ONCOLOGY Comments Off on in Patients with Rheumatoid Arthritis and Osteoarthritis

Parameter Group EO EC BF R (mm) Controls 2.0 1.9 2.3 #,$ (1.7–2.6) (1.6–2.6) (1.8–2.8) OA 2.7** 2.8*** 3.2***,## (2.4–3.4) (2.2–3.8) (2.5–4.1) RA 2.6** 2.8** 3.3***,###,$$ (2.1–3.4) (2.1–3.4) (2.7–4.1) A…

read more

in Sarcoidosis and Exercise Tolerance, Dyspnea, and Quality of Life

Oct 9, 2016 by in ONCOLOGY Comments Off on in Sarcoidosis and Exercise Tolerance, Dyspnea, and Quality of Life

  Sarcoidosis Controls p (n = 111) (n = 65) Age (years) 44.8 ± 10.4 43.3 ± 12.4  BMI (kg/m2) 28.2 ± 3.9 26.8 ± 5.6 0.091 FAS 22.9 ± 7.9 17.0 ± 3.3 0.046 MRC 1.3 ± 0.8 1.1 ± 0.3 0.028 OCD 1.6 ± 0.8 1.1 ± 0.3 0.025 Borg’s scale 0.7 ± 1.3…

read more

Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis

Oct 9, 2016 by in ONCOLOGY Comments Off on Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis

© Springer International Publishing Switzerland 2014Mieczyslaw Pokorski (ed.)Lung Cancer and Autoimmune DisordersAdvances in Experimental Medicine and Biology83310.1007/5584_2014_17 The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis D. Boruczkowski1  ,…

read more

rs1800471 Polymorphism of TGFB1 Gene, Serum TGF-Beta1 Level and Chronic Kidney Disease Progression

Oct 9, 2016 by in ONCOLOGY Comments Off on rs1800471 Polymorphism of TGFB1 Gene, Serum TGF-Beta1 Level and Chronic Kidney Disease Progression

  Rapid progression (n = 54) Slow progression (n = 55) p Age at examination (years) 14.6 ± 7.5 16.5 ± 5.1 NS (0.7–24.0) (7.3–25.0) NS Age at CKD diagnosis (years) 9.9 ± 6.8 5.6 ± 6.1 0.001 (0.01–22.0) (0.1–20.0) Etiology of…

read more
Get Clinical Tree app for offline access